<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Beclomethasone (nasal): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Beclomethasone (nasal): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Beclomethasone (nasal): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8871" href="/d/html/8871.html" rel="external">see "Beclomethasone (nasal): Drug information"</a> and <a class="drug drug_patient" data-topicid="11052" href="/d/html/11052.html" rel="external">see "Beclomethasone (nasal): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F7990246"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Beconase AQ [DSC];</li>
<li>Qnasl;</li>
<li>Qnasl Childrens</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869069"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Beclomethasone AQ;</li>
<li>MYLAN-Beclo AQ</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10470857"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Corticosteroid, Intranasal</span></li></ul></div>
<div class="block dop drugH1Div" id="F7991817"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Product formulations are not interchangeable: Beconase AQ: One spray delivers 42 mcg; Qnasl: One spray delivers 40 mcg or 80 mcg</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="baa64232-71eb-4ed2-b997-b86ca190c67b">Nasal airway obstruction/adenoidal hypertrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasal airway obstruction/adenoidal hypertrophy:</b> Limited data available; dosing regimens variable: Intranasal: Beconase AQ (42 mcg/spray): Children 5 to 12 years: Initial: 2 sprays (84 mcg) <b>per nostril</b> twice daily (total dose: 336 mcg daily) for 4 weeks, followed by 1 spray (42 mcg) <b>per nostril</b> twice daily (total dose: 168 mcg daily). Dosing based on a double-blind, placebo-controlled crossover study (n=17, age range: 5 to 11 years); results showed significant reduction in adenoid hypertrophy and related obstructive nasal symptoms following 4 weeks of beclomethasone therapy vs placebo (Demain 1995). Positive efficacy findings were also observed in a single-blind, placebo-controlled crossover study of 53 children (mean age: 3.8 ± 1.3 years) using a total daily dose of 400 mcg/day (200 mcg twice daily [using 50 mcg/spray formulation, not available in US]) delivered as 100 mcg (2 sprays) <b>per nostril</b> twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12612277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12612277'])">Ref</a></span>). Lower daily dosage (200 mcg/day) have not been found effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23119911']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23119911'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="472e5c97-0a0a-4cfa-8a41-b487184d43de">Nasal polyps, vasomotor rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasal polyps (postsurgical prophylaxis), vasomotor rhinitis:</b> Intranasal: Beconase AQ (42 mcg/spray):</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 12 years: Initial: 1 spray (42 mcg) <b>per nostril</b> twice daily (total dose: 168 mcg daily); if response inadequate, may increase to 2 sprays (84 mcg) <b>per nostril</b> twice daily (total dose: 336 mcg daily); once symptoms are adequately controlled, decrease dose to 1 spray (42 mcg) <b>per nostril</b> twice daily (total dose: 168 mcg daily).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents ≥12 years: 1 or 2 sprays (42 mcg or 84 mcg) <b>per nostril</b> twice daily (total dose: 168 to 336 mcg daily); maximum daily dose: 336 mcg/<b>day</b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54680997-14b0-467f-9b8c-4cb52605d7f8">Allergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>A</b>
<b>llergic r</b>
<b>hinitis</b>
<b>:</b> Intranasal:</p>
<p style="text-indent:-2em;margin-left:4em;">Beconase AQ (42 mcg/spray):</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to &lt;12 years: Initial: 1 spray (42 mcg) <b>per nostril</b> twice daily (total dose: 168 mcg daily); if response inadequate, may increase to 2 sprays (84 mcg) <b>per nostril</b> twice daily (total dose: 336 mcg daily); once symptoms are adequately controlled, decrease dose to 1 spray (42 mcg) <b>per nostril</b> twice daily (total dose: 168 mcg daily).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: 1 or 2 sprays (42 mcg or 84 mcg) <b>per nostril</b> twice daily (total dose: 168 to 336 mcg daily); maximum daily dose: 336 mcg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Qnasl:</p>
<p style="text-indent:-2em;margin-left:6em;">Children 4 to &lt;12 years: Qnasl 40 mcg: 1 spray (40 mcg) <b>per nostril</b> once daily (total dose: 80 mcg/day); maximum daily dose: 80 mcg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Qnasl 80 mcg: 2 sprays (160 mcg) <b>per nostril</b> once daily (total daily dose: 320 mcg/day); maximum daily dose: 320 mcg/<b>day</b></p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51073392"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51073393"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F7991818"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8871" href="/d/html/8871.html" rel="external">see "Beclomethasone (nasal): Drug information"</a>)</p>
<p style="text-indent:0em;">
<b>Note:</b> For patients with mucous crusting, rinsing with saline nasal spray before administration can remove mucous crusting and improve nasal coating (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-deShazo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-deShazo.1'])">Ref</a></span>). If nasal obstruction is so severe that sprays cannot penetrate when treating rhinitis, consider concomitant use of an intranasal decongestant for up to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32707227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32707227'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54680997-14b0-467f-9b8c-4cb52605d7f8">Allergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Beconase AQ: Intranasal: 1 or 2 inhalations (42 or 84 mcg) in each nostril twice daily; total dose: 168 to 336 mcg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">Qnasl: Intranasal: 2 inhalations (160 mcg) in each nostril once daily (maximum: 320 mcg/day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef40a39c-9ea3-4ff6-810a-a525dd53d280">Nasal polyps</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasal polyps (postsurgical prophylaxis):</b> Beconase QA: Intranasal: 1 or 2 inhalations (42 or 84 mcg) in each nostril twice daily; total dose: 168 to 336 mcg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1820e284-41e2-4255-93fb-309e4d01aef5">Nonallergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonallergic rhinitis:</b> Beconase AQ: Intranasal: 1 or 2 inhalations (42 or 84 mcg) in each nostril twice daily; total dose: 168 to 336 mcg/day.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990549"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987887"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F7991707"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Respiratory: Nasopharyngitis (≤24%; children: 2%), epistaxis (2% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (≤5%), headache (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenal suppression (at high doses or in susceptible individuals), hypercorticoidism (at high doses or in susceptible individuals)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (≤5%), oral candidiasis (rare; more likely with aqueous solution)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Immunosuppression</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Decreased linear skeletal growth rate</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Intraocular pressure increased (5%), lacrimation (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sneezing (4%), upper respiratory tract infection (children: 3%), nasal congestion (≤3%), rhinorrhea (≤3%), nasal mucosa irritation (erosion) (≤1%), nasal candidiasis (rare; more likely with aqueous solution), pharyngeal candidiasis (rare; more likely with aqueous solution)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children: 3%), wound healing impairment</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Ageusia, altered sense of smell, anaphylactoid reaction, anaphylaxis, angioedema, anosmia, blurred vision, bronchospasm, burning sensation, cataract, chorioretinitis, dry nose, glaucoma, hypersensitivity reaction, nasal mucosa ulcer, nasal septum perforation, skin rash, unpleasant taste, urticaria, wheezing</p></div>
<div class="block coi drugH1Div" id="F7991691"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to beclomethasone or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Tuberculosis (TB) infection (latent TB) or disease (active TB), or untreated fungal, bacterial and viral infections.</p></div>
<div class="block war drugH1Div" id="F7991692"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed wound healing: Avoid nasal corticosteroid use in patients with recent nasal septal ulcers, nasal surgery or nasal trauma until healing has occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions (including anaphylaxis, angioedema, rash, urticaria, and wheezing) have been reported; discontinue for severe reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infections, mask an acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines; avoid exposure to chickenpox and/or measles, especially if not immunized. Avoid use or use with caution in patients with tuberculosis (TB) infection (latent TB) or disease (active TB), untreated bacterial or fungal infections (local or systemic), viral or parasitic infections, or ocular herpes simplex.</p>
<p style="text-indent:-2em;margin-left:4em;">• Local nasal effects: Nasal septal perforation and localized Candida albicans infections of the nose and/or pharynx may occur. Nasal discomfort, epistaxis, and nasal ulceration may also occur; periodically examine nasal mucosa in patients on long-term therapy. Monitor patients for adverse nasal effects; discontinuation of therapy may be necessary if an infection occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Increased intraocular pressure, open-angle glaucoma, and/or cataracts have occurred with intranasal corticosteroid use; use with caution in patients with a history of increased intraocular pressure, cataracts and/or glaucoma. Consider routine eye exams in chronic users or in patients who report visual changes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Rhinitis: Do not use in the presence of untreated localized infection involving the nasal mucosa. Do not continue use beyond 3 weeks in the absence of significant symptomatic improvement. Symptomatic relief may not occur for as long as 2 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Nasal polyps: Treatment may need to be continued for several weeks or more before a therapeutic result can be fully assessed. Treatment of nasal polyps with beclomethasone should be considered adjunctive therapy to surgical removal and/or the use of other medications that will permit effective penetration of beclomethasone into the nose. Recurrence can occur after stopping treatment.</p></div>
<div class="block dosfc drugH1Div" id="F21005920"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Beconase AQ 25 g canisters contain 180 sprays.</p>
<p style="text-indent:-2em;margin-left:2em;">Qnasl 6.8 g canisters contains 60 actuations and the 10.6 g canisters contain 120 actuations.</p></div>
<div class="block foc drugH1Div" id="F7991835"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Solution, Nasal, as dipropionate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Qnasl: 80 mcg/actuation (10.6 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Qnasl Childrens: 40 mcg/actuation (6.8 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Nasal, as dipropionate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Beconase AQ: 42 mcg/spray (25 g [DSC]) [contains benzalkonium chloride]</p></div>
<div class="block geq drugH1Div" id="F7990249"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F7991837"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol solution</b> (Qnasl Childrens Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mcg/ACT (per gram): $53.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol solution</b> (Qnasl Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mcg/ACT (per gram): $34.46</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869070"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mcg/actuation (1 ea, 22 mL)</p></div>
<div class="block adip drugH1Div" id="F53569731"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">When used short term as adjunctive therapy in acute bacterial rhinosinusitis (ABRS), intranasal steroids show modest symptomatic improvement and few adverse effects; improvement is primarily due to increased sinus drainage. Use should be considered optional in ABRS; however, intranasal corticosteroids should be routinely prescribed to ABRS patients who have a history of or concurrent allergic rhinitis (Chow 2012).</p></div>
<div class="block admp drugH1Div" id="F52614318"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For intranasal use only. Shake well prior to each use. Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Avoid spraying directly onto the nasal septum or into eyes. Discard after the "discard by" date or after labeled number of doses has been used, even if bottle is not completely empty.</p>
<p style="text-indent:-2em;margin-left:2em;">Beconase AQ: Prior to initial use, prime pump 6 times (or until fine spray appears); repeat priming if product not used for ≥7 days. Nasal applicator and dust cap may be washed in warm water and dried thoroughly.</p>
<p style="text-indent:-2em;margin-left:2em;">Qnasl: Spray in nostril(s); avoid spraying in eyes or mouth. Do not blow nose for 15 minutes following administration. Do not wash or put any part of canister or actuator in water; wipe nasal tip with clean, dry tissue or cloth.</p></div>
<div class="block adm drugH1Div" id="F7991821"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Beconase AQ: Shake well prior to each use. Prior to initial use, prime pump 6 times (or until fine spray appears); repeat priming if product not used for ≥7 days. Spray in nostril(s); avoid spraying in eyes or mouth. Nasal applicator and dust cap may be washed in warm water and dry thoroughly.</p>
<p style="text-indent:-2em;margin-left:2em;">Qnasl: Spray in nostril(s); avoid spraying in eyes or mouth.</p></div>
<div class="block sts drugH1Div" id="F7991716"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Beconase AQ: Store between 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Qnasl: Store between 20°C and 25°C (68°F and 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Do not puncture. Do not store near heat or open flame. Do not expose to temperatures higher than 49°C (120°F).</p></div>
<div class="block usep drugH1Div" id="F53570422"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Beconase AQ: Management of nasal symptoms associated with seasonal or perennial allergic and nonallergic (vasomotor) rhinitis and prevention of recurrence of nasal polyps following surgical removal (FDA approved in ages ≥6 years and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Qnasl: Management of nasal symptoms associated with seasonal and perennial allergic rhinitis (FDA approved in ages ≥4 years and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Intranasal corticosteroids have also been used for the following: As an adjunct to antibiotics in empiric treatment of acute bacterial rhinosinusitis primarily in patients (adolescents and adults) with a history of allergic rhinitis (AAP [Wald 2013]; Chow 2012); however, data in children showing adjunct therapy is beneficial are less conclusive (AAP [Wald 2013]); in pediatric patients with mild obstructive sleep apnea syndrome who cannot undergo adenotonsillectomy or who still have symptoms after surgery (Marcus 2012); and for children with nasal obstruction caused by adenoidal hypertrophy.</p></div>
<div class="block cyt drugH1Div" id="F13298818"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9770054"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: Corticosteroids (Nasal) may diminish the therapeutic effect of Esketamine.  Management: Patients who require a nasal corticosteroid on an esketamine dosing day should administer the nasal corticosteroid at least 1 hour before esketamine.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F7991687"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Intranasal corticosteroids may be acceptable for the treatment of rhinitis during pregnancy when used at recommended doses (Lal 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnant females adequately controlled on beclomethasone may continue therapy; if initiating treatment during pregnancy, use of an agent with more data in pregnant females and less systemic absorption may be preferred (Alhussien 2018; Namazy 2016).</p></div>
<div class="block mopp drugH1Div" id="F53570399"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Mucous membranes for signs of fungal infection, growth (pediatric patients), signs/symptoms of HPA axis suppression/adrenal insufficiency; ocular changes</p></div>
<div class="block pha drugH1Div" id="F7991717"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation</p></div>
<div class="block phk drugH1Div" id="F7991772"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Within a few days up to 2 weeks</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Beclomethasone dipropionate (BDP): 20 L; Beclomethasone-17-monopropionate (17-BMP): 424 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: BDP 87%; 17-BMP: 94% to 96% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: BMP is a prodrug (inactive); undergoes rapid conversion to 17-BMP (major active metabolite) during absorption; followed by additional metabolism via CYP3A4 to other, less active metabolites (beclomethasone-21-monopropionate [21-BMP] and beclomethasone [BOH])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 17-BMP: 44% (43% from swallowed portion)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: BDP: 0.5 hours; 17-BMP: 2.7 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (60%); urine (&lt;10% to 12%; as free and conjugated metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961957"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Beclomet aqua</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Aldecin aqueous | Beconase | Beconase allergy &amp; hayfever 12 hour | Beconase aqueous</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Beconase AQ | Becospray | Decomit</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Beclometatop | Beconase</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Humex rhume des foins a la beclometasone</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Beconase</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Beclosol aquoso | Clenil nasal aquoso</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Beconase | Beconasol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Beconase</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Beclometasona | Beclometasona dipropionato | Beclomex | Beclort aqua | Beconase AQ | Rinoclenil</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Beclomet | Nasobec</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Beclomet | Beclometason | Beclometason ct | Beconase | Otri allergie | Otriven Allergie Aktiv mit Beclometason | Ratioallerg</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Becotide</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aldecina | Beconase</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Beconase aqua</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Beclonasal | Beconase | Nasobec</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Beclo</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Beclonasal | Beconase</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Beclo Rhino | Beconase | Humex rhume des foins a la beclometasone | Rinoclenil</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Beclo aqua | Beclometasone | Beclomethasone | Beclomethasone cox | Beclomist | Beconase | Beconase Hayfever | Boots hayfever &amp; allergy relief | Hayfever Relief | Nasobec aqueous | Nasobec hayfever | Rino clenil aqueou | Vivabec | Zonivent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Iriniozol | Rinosol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Aldecin | Beclate | Beconase | Nasobec</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Beclonasal aqua</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Beclomet | Beconase</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Beclo Rhino | Beclomethasone Dipropionate | Beconase | Beconase allergy | Beconase Hayfever | Nasobec</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Beconase</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Beclate | Beclate aquanase | Econase</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Rino Clenil | Rinoclenil</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Albezon | Aldecin | Alroyer | Beclometasone | Becloze aq | Espetat aq | Espetat aq maruko | Espetat aq merck hoei | Espetat aq teikoku | Espetat aq yoshindo | Espetat aq zensei | Mily | Mily merck hoei | Nanadora | Nazal alpha AR C | Penbulin | Taunus | Taunus amel | Taunus aqua | Taunus nikken</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Beclate aquanase | Becort aquanase | Decomit</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Beconase | Nasobec aqueous | Rinoclenil</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Beconase | Rinoclenil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Beclomet aqua | Beclonasal | Beconase</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Beconase</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Beclate aquanase | Beclonasal | Beconase</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Beconase</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Beclometasona | Beconase | Beconase aqua | Rinoclenil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo-beclomethasone | Beclate | Beclomet | Beconase | Belax | Rino Clenil</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Beclometason | Beclometason Nevel | Beconase | Beconase aqueous nevel | Beconase nevel | Viarin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Becotide</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Alanase aqueous | Aldecin aqueous | Atomase | Becloclear | Beconase</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Beconase aqua | Rinoclenil</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Beconase</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Beclo Rino | Gnadion</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Beconase | Nasobec</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Beconase AQ | Qnasl | Vancenase AQ</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Beconase</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Rinosol</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Beclocort | Beconase Aqueous Spray | Nasobec Aqueous Spray | Rinobek</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aldecin | Beclometasone orion | Beclomethasone orion pharma | Beconase | Nasobec</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-beclomethasone | Rinoclenil</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Becotide</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Beconase | Decomit</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Beconase</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Nasobec</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Beclate | Beclomet | Beclomet nasal aqua | Beclomet nasal aqua spray | Beclomethasone jewim | Beconase aqueous nasal spray | Bemase | Dipronase | Rino Clenil | Rinoclenil</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Beclomax | Beclosp | Beconase | Beklomil | Nazobec | Rinobek | Rinoclenil | Rinomil | Zonabec</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Aldecin | Beclomet | Beconase | Becoton | Belax | Betonase aqueous | Nosecone</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Beclometasone | Beconase</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Beclate</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Beconase AQ | Nasair acuoso | Rinoclenil | Rinoclenil acuoso</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Meclonate</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Anceron | Beclate | Beconase | Ciplanaze multicare | Clenil | Nobec | Rolab-beclomethasone | Ventnaze | Viarox | Viarox aq</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Clenil</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Beclate | Beclate aquanase</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29164323">
<a name="29164323"></a>Alhussien AH, Alhedaithy RA, Alsaleh SA. Safety of intranasal corticosteroid sprays during pregnancy: an updated review. <i>Eur Arch Otorhinolaryngol</i>. 2018;275(2):325-333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/29164323/pubmed" id="29164323" target="_blank">29164323</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Beclomethasone nasal spray [product monograph]. Weston, Ontario, Canada: Apotex Inc; September 2020.</div>
</li>
<li>
<div class="reference">
                  Beconase AQ (beclomethasone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis</i>. 2012;54(8):e72-e112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12612277">
<a name="12612277"></a>Criscuoli G, D'Amora S, Ripa G, et al. Frequency of Surgery Among Children Who Have Adenotonsillar Hypertrophy and Improve After Treatment With Nasal Beclomethasone. <i>Pediatrics.</i> 2003;111(3):e236-e238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/12612277/pubmed" id="12612277" target="_blank">12612277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7862473">
<a name="7862473"></a>Demain JG, Goetz DW. Pediatric Adenoidal Hypertrophy and Nasal Airway Obstruction: Reduction With Aqueous Nasal Beclomethasone. <i>Pediatrics.</i> 1995;95(3):355-364.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/7862473/pubmed" id="7862473" target="_blank">7862473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-deShazo.1">
<a name="deShazo.1"></a>deShazo RD, Kemp SF. Pharmacotherapy of allergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 18, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. <i>J Allergy Clin Immunol.</i> 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2646995">
<a name="2646995"></a>Kobayashi RH, Tinkelman DG, Reese ME, et al. Beclomethasone Dipropionate Aqueous Nasal Spray for Seasonal Allergic Rhinitis in Children. <i>Ann Allergy.</i> 1989;62(3):205-208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/2646995/pubmed" id="2646995" target="_blank">2646995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26800862">
<a name="26800862"></a>Lal D, Jategaonkar AA, Borish L, et al. Management of rhinosinusitis during pregnancy: systematic review and expert panel recommendations. <i>Rhinology</i>. 2016;54(2):99-104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/26800862/pubmed" id="26800862" target="_blank">26800862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23119911">
<a name="23119911"></a>Lepcha A, Kurien M, Job A, et al. Chronic Adenoid Hypertrophy in Children - Is Steroid Nasal Spray Beneficial? <i>Indian J Otolaryngol Head Neck Surg. </i>2002;54(4):280-284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/23119911/pubmed" id="23119911" target="_blank">23119911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22926173">
<a name="22926173"></a>Marcus CL, Brooks LJ, Draper KA, et al. Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome. <i>Pediatrics.</i> 2012;130(3):576-584.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/22926173/pubmed" id="22926173" target="_blank">22926173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27012010">
<a name="27012010"></a>Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. <i>J Investig Allergol Clin Immunol</i>. 2016;26(1):1-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/27012010/pubmed" id="27012010" target="_blank">27012010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Qnasl.1">
<a name="Qnasl.1"></a>Qnasl (beclomethasone) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832968">
<a name="25832968"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(2)(suppl):S1-S39. doi:10.1177/0194599815572097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/25832968/pubmed" id="25832968" target="_blank">25832968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23796742">
<a name="23796742"></a>Wald ER, Applegate KE, Bordley C, et al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. <i>Pediatrics</i>. 2013;132(1):e262-280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/23796742/pubmed" id="23796742" target="_blank">23796742</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15947 Version 187.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
